A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The objectives of this clinical trial are:
- to evaluate whether a 12 month treatment with ladarixin is effective to improve glycemic
control in newly diagnosed T1D adult patients with preserved beta-cell function.
- to evaluate the safety of ladarixin in the specific clinical setting